Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 12-Month Low – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares hit a new 52-week low during trading on Friday . The company traded as low as $16.03 and last traded at $16.25, with a volume of 2375 shares traded. The stock had previously closed at $16.67.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AAPG. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. BTIG Research reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Finally, B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Performance

The firm has a 50-day moving average of $18.18 and a 200 day moving average of $20.51. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million during the quarter. As a group, research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Group AG increased its stake in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the period. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the second quarter valued at approximately $391,000. Finally, Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International in the third quarter valued at approximately $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.